<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-11-18" updated="2020-01-02">
  <drugbank-id primary="true">DB05293</drugbank-id>
  <name>IDM-2</name>
  <description>IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.</description>
  <cas-number/>
  <unii/>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3342</ref-id>
        <pubmed-id>16164034</pubmed-id>
        <citation>Baron-Bodo V, Doceur P, Lefebvre ML, Labroquere K, Defaye C, Cambouris C, Prigent D, Salcedo M, Boyer A, Nardin A: Anti-tumor properties of human-activated macrophages produced in large scale for clinical application. Immunobiology. 2005;210(2-4):267-77.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in bladder cancer.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>MAK cells are produced ex-vivo from macrophages taken from the patient that are activated with the use of gamma interferon, a synthetic version of a natural activator. Following surgery for bladder cancer, IDM-2 is instilled directly into the bladder.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands>
    <international-brand>
      <name>Bexidem</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910061</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>